Abstract: There are provided compositions comprising Such compositions can also further comprise various components such as lipids (for example fatty acids, esters thereof or derivatives thereof). Such compositions can be used for example in methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism.
Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
Type:
Application
Filed:
May 12, 2016
Publication date:
January 19, 2017
Inventors:
James T. Dalton, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy
Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
Type:
Application
Filed:
June 23, 2016
Publication date:
January 19, 2017
Inventors:
James T. DALTON, Thamarai PONNUSAMY, Ramesh NARAYANAN
Abstract: Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.
Type:
Application
Filed:
March 12, 2015
Publication date:
January 19, 2017
Inventors:
Patrycja Nowak-Sliwinska, Paul Dyson, Arjan Griffioen, Andrea Weiss, Hubert Van den Bergh, Xianting Ding
Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Abstract: The present invention provides compositions that are substantially niacin free for treating dyslipidemia and/or inflammation in a subject. Compositions of the invention include a therapeutically effective amount of a mixture phytosomes obtained from quercetin and at least one other phytosome obtained from the group consisting of curcurmin, green tea, and a combination thereof. The present invention also provides a method for treating dyslipidemia and/or inflammation in a subject.
Type:
Application
Filed:
July 13, 2015
Publication date:
January 19, 2017
Applicant:
THORNE RESEARCH, INC.
Inventors:
Bodi Zhang, Michael A Schmidt, Mark Houston, Robert Rountree
Abstract: The present invention provides a compound of formula (I) as a SERCA inhibitor for treating cancers, a pharmaceutical composition comprising said compound, and methods of using said compound for treating cancers and/or inducing cell death in cells of said cancers. Said cancers include but not limited to cervical, lung, liver, breast, and prostate cancer. Said cancers also include drug-resistant and/or apoptosis-resistant cancers such as isogenic drug-resistant colon cancer. The subject being administered with said compound or the composition comprising thereof can be human or animal subject. Said methods for treating cancers and/or inducing cell death can be a targeting treatment for certain cancers.
Abstract: A method and compositions for treating cancer is described using at least two epigenetic modifiers. In various embodiments, hyperbaric oxygen therapy and glycolytic inhibition therapy are used as well.
Abstract: The invention relates to a complex of an anthocyanidin and a methylated ?-cyclodextrin which can be formulated as an aqueous solution and as a solid, and to a process for the preparation of such a complex. Complexes according to the invention are storage-stable and can be readily formulated in aqueous solution.
Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
Type:
Application
Filed:
March 5, 2015
Publication date:
January 19, 2017
Inventors:
Ali Turkyilmaz, Ali Hasan Turp, Mehtap Saydam, Onur Ulgen
Abstract: The present invention relates to a process for preparing a pharmaceutical composition of vildagliptin under oxygen free inert gas atmosphere. The present invention particularly relates to a pharmaceutical composition of vildagliptin obtained by the process which is stable to oxygen physiologically and chemically.
Type:
Application
Filed:
March 5, 2015
Publication date:
January 19, 2017
Inventors:
Ali Turkyilmaz, Gulay Yelken, Mehtap Saydam, Onur Ulgen
Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
Type:
Application
Filed:
May 18, 2016
Publication date:
January 19, 2017
Inventors:
Riccardo Giovannini, Yunhai Cui, Henri Doobs, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
Abstract: Disclosed herein are self-emulsifying compositions and formulations of Diindolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.
Abstract: The invention described herein provides a solid dispersion of Indirubin, a pharmaceutical composition comprising the solid dispersion of Indirubin, a process for preparing the solid dispersion and pharmaceutical composition, and a method of using the pharmaceutical composition.
Abstract: A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, therby preventing tumor cell extravasation.
Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment and prophylaxis of visual hallucinations associated with Lewy Body dementia.
Type:
Application
Filed:
July 15, 2016
Publication date:
January 19, 2017
Inventors:
Lawrence Tim FRIEDHOFF, Shankar RAMASWAMY, Yandong WEN
Abstract: The present disclosure provides compositions and methods for treating multidrug-resistant nephrotic syndrome (MDR-NS) in pediatric subjects comprising atrasentan. Methods of reducing protenuria in a pediatric patient having MDR-NS are also provided.
Type:
Application
Filed:
July 15, 2016
Publication date:
January 19, 2017
Inventors:
John J. Brennan, Franz Schaefer, Melissa E. Wigderson
Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Application
Filed:
June 16, 2016
Publication date:
January 19, 2017
Applicant:
NOVARTIS AG
Inventors:
Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef Troxler, Joe WRIGGLESWORTH
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Type:
Application
Filed:
March 23, 2016
Publication date:
January 19, 2017
Applicant:
MediciNova, Inc.
Inventors:
Michael E. KALAFER, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of SGK1 are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of SGK1 inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, SGK1 inhibitors also have Glucocorticoid Receptor (GR) and/or Androgen Receptor (AR) inhibitory activity or are administered in conjunction with GR and/or AR inhibitors.
Abstract: Methods of treating a developmental disorder such as Dravet syndrome by administering a pharmaceutical composition of gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.
Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.
Abstract: An object of the present invention is to provide a novel endoparasite control agent as a parasiticide, an antiprotozoal or the like. Provided is an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I): or a salt thereof as an active ingredient.
Type:
Application
Filed:
September 15, 2016
Publication date:
January 19, 2017
Inventors:
Kiyoshi Kita, Akiyuki Suwa, Masatsugu Oda, Koji Tanaka
Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
Abstract: Disclosed are methods and compositions for treating or preventing a disease or disorder responsive to a decrease in baseline mitochondrial iron in a subject in need thereof. The methods typically include administering a pharmaceutical composition comprising a mitochondrial permeable iron chelator to the subject.
Abstract: The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.
Type:
Application
Filed:
July 13, 2016
Publication date:
January 19, 2017
Inventors:
Sateesh Kandavilli, Franklin Okumu, Manish M. Banker, Sujit Kumar Dolai
Abstract: The present invention provides a method of treating or preventing hyperlipidemia in a subject in need thereof. Such method includes, specifically, administrating to the subject a therapeutically effective amount of a caffeamide derivative. The present invention also provides a pharmaceutical composition containing, primarily, the caffeamide derivative. The method and pharmaceutical composition of the present invention can effectively and significantly lower the high-fat diet-induced body weight gain and absolute visceral fat weight as well as the concentration of triglycerides and free fatty acids in blood, and levels of total lipid and triacylglycerol in liver tissue. In addition, the caffeamide of the present invention also reduces size of adipocyte, hepatocellular ballooning phenomenon, and liver steatosis.
Abstract: The present application relates to methods of treating, preventing, delaying the onset of, reducing the incidence of, or reducing the severity of fibrosis, obesity and conditions associated with post-menopausal obesity.
Type:
Application
Filed:
February 9, 2016
Publication date:
January 19, 2017
Inventors:
James T. Dalton, Ramesh Narayanan, Muralimohan Yepuru
Abstract: Provided herein are methods for treating cancer relating to inhibition of PI3K, as pharmaceutical compositions comprising a PI3K inhibitor and a PAK1 inhibitor.
Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
Type:
Application
Filed:
September 30, 2016
Publication date:
January 19, 2017
Inventors:
Serengulam V. Govindan, David M. Goldenberg
Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
Type:
Application
Filed:
September 28, 2016
Publication date:
January 19, 2017
Inventors:
Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, for use in the prevention or treatment of an ataxic disorder.
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Application
Filed:
July 13, 2016
Publication date:
January 19, 2017
Inventors:
Yao-Ling Qiu, Hui Cao, Wei Li, Xiaowen Peng, Meizhong Jin, Jorden Kass, Xuri Gao, Yat Sun Or
Abstract: The present disclosure relates to methods of treating inflammation in a subject. Particularly, the disclosure provides methods for treating inflammation by administering pharmaceutically active serelaxin in order to increase a soluble marker associated with reducing inflammation. Further encompassed in the present disclosure are method for treating inflammatory disorders and kits for administering pharmaceutically active serelaxin to subjects suffering from such disorders.
Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
Type:
Application
Filed:
September 29, 2016
Publication date:
January 19, 2017
Applicants:
Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
Inventors:
Bernard S. GREEN, Galia LUBOSHITS, Michael A. FIRER
Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
Type:
Application
Filed:
June 9, 2016
Publication date:
January 19, 2017
Applicant:
Rexahn Pharmaceuticals, Inc.
Inventors:
Young Bok Lee, Deog Joong Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
Abstract: A program for outpatient modified rapid detoxification for addiction to alcohol and drugs is disclosed. Patients are seen by trained medical professionals who are recovering addicts and alcoholics. The medication protocol addresses all of the withdrawal symptoms while allowing the patient to safely sleep through the detoxification.
Abstract: Novel RET fusion molecules and uses are disclosed. In one embodiment, a KIF5B-RET fusion includes an in-frame fusion of an exon of KIF5B (e.g., one or more exons encoding a kinesin motor domain or a fragment thereof) and an exon of RET (e.g., one or more exons encoding a RET tyrosine kinase domain or a fragment thereof). For example, the KIF5B-RET fusion can include an in-frame fusion of at least exon 15 of KIF5B or a fragment thereof (e.g., exons 1-15 of KIF5B or a fragment thereof) with at least exon 12 of RET or a fragment thereof (e.g., exons 12-20 of RET or a fragment thereof).
Type:
Application
Filed:
February 17, 2016
Publication date:
January 19, 2017
Inventors:
Sean R. Downing, Matthew J. Hawryluk, Doron Lipson, Alexander N. Parker, Philip James Stephens
Abstract: A pharmaceutical composition including trametinib or a pharmaceutically acceptable salt thereof as active ingredient and a carrier is described herein. Also described is an intermediate for the preparation of the pharmaceutical composition and a method of preparing the pharmaceutical composition or the intermediate.
Abstract: The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.
Type:
Application
Filed:
August 29, 2016
Publication date:
January 19, 2017
Inventors:
KATHERINE L. RADTKE, KARTIK TEMBURNIKAR
Abstract: Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain L-methionine.
Abstract: A pharmaceutical administration system for the transdermal application of at least one active agent includes vardenafil and/or a pharmaceutically acceptable salt thereof as the active agent and a pharmaceutically acceptable carrier providing a solution of the at least one active agent in the administration system. Another active agent may be testosterone. This system can be used to systemically deliver therapeutic doses of vardenafil and/or a pharmaceutically acceptable salt thereof and optionally testosterone in order to treat benign prostatic hyperplasia, erectile dysfunction, male hypogonadism, pulmonary hypertension, and/or pulmonary arterial hypertension.